| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Boc-L-Dap-OH does not have a defined biological target as it is a protected amino acid building block rather than a pharmacologically active compound. Its function is chemical—it serves as a building block for the synthesis of peptides and peptide-based drug candidates. The Boc group protects the α-amino group during peptide synthesis, while the β-amino group is available for selective functionalization. When incorporated into peptides, the DAP residue can introduce metal complexing groups or serve as a site for further modification. The compound itself is not evaluated for biological activity against specific targets.
|
|---|---|
| ln Vitro |
As a chemical intermediate, Boc-L-Dap-OH exhibits no intrinsic pharmacological activity in vitro. Its utility is demonstrated in solid-phase peptide synthesis for the preparation of peptides with metal complexing groups, gramicidin S cyclic analogs with antibiotic and hemolytic activities, HCV protease inhibitor modified analogs, and peptidic V1a receptor agonists. The compound is used in the synthesis of glucosamine synthase inhibitors and a myosin kinase inhibitor. In cell-based assays, the compound itself is not tested for biological activity. Instead, the peptides synthesized from this building block are evaluated for their pharmacological properties.
|
| ln Vivo |
Boc-L-Dap-OH does not exhibit in vivo biological activity as it is not a therapeutic agent. The compound is used as a building block for the synthesis of peptide-based drug candidates. Any in vivo effects would be associated with the final peptides synthesized from this building block, not with the building block itself. The compound is not administered to animals in pharmacological studies and has no known physiological effects. Its role is strictly chemical—providing a protected DAP residue for peptide synthesis.
|
| Enzyme Assay |
In vitro assays for Boc-L-Dap-OH focus on its use in solid-phase peptide synthesis rather than receptor binding. A standard protocol involves using the compound as a building block in automated peptide synthesizers. The Boc group is removed by TFA treatment, and the free amine is coupled with the next amino acid using standard coupling reagents (HBTU, HATU, or DIC). The compound is used in the synthesis of peptides with metal complexing groups and various biologically active peptide analogs. Quality control includes HPLC (>98% purity), melting point determination, and optical rotation measurement.
|
| Cell Assay |
In vitro cell culture experiments with Boc-L-Dap-OH derivatives typically involve testing the biological activity of peptides synthesized from this building block. Peptides are tested in cell culture using standard protocols for their specific biological activities (e.g., antibiotic activity against bacteria, hemolytic activity against red blood cells, or receptor agonist activity). Cells are cultured in appropriate media and treated with peptides at concentrations ranging from 0.1-100 µM for 24-72 hours. Cell viability and specific biological readouts are measured using appropriate assays. The building block itself is not evaluated in cellular systems.
|
| Animal Protocol |
In vivo animal studies are not conducted with Boc-L-Dap-OH itself, as it is a building block for peptide synthesis. When the compound is used to synthesize peptide drug candidates, those final products undergo standard preclinical evaluation. Typical protocols for peptide drug candidates include pharmacokinetic studies in rodents (intravenous or subcutaneous administration, blood sampling for LC-MS/MS analysis), efficacy studies in disease models, and toxicology studies. These studies evaluate the safety and efficacy of the final peptides, not the synthetic building block.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Boc-L-Dap-OH are not characterized as it is not a drug substance. Based on its physicochemical properties (molecular weight 204.20, logP approximately 0.5-1.0), the compound would be expected to have moderate oral bioavailability if administered. The Boc group would likely be cleaved in vivo to release the free diaminopropionic acid, which would be metabolized via normal amino acid pathways. However, the compound is not intended for human exposure and has not been evaluated in formal pharmacokinetic studies. For peptide drug candidates synthesized from this building block, pharmacokinetic properties are determined as part of drug development.
|
| Toxicity/Toxicokinetics |
Boc-L-Dap-OH has a WGK Germany classification of 3 and is a combustible solid (storage class 11). Standard laboratory safety precautions should be followed when handling this compound, including the use of gloves, safety glasses, and type N95 respirators. The compound should be stored in a cool, dry place away from moisture and strong oxidizing agents. No acute toxicity data are available. The compound is not intended for drug, household, or other uses.
|
| Additional Infomation |
Boc-L-Dap-OH is a monoprotected derivative of 2,3-diaminopropionic acid (DAP) used in solid-phase peptide synthesis. It is also known as Nα-Boc-L-2,3-diaminopropionic acid. The compound is used in the synthesis of peptides with metal complexing groups, glucosamine synthase inhibitors, myosin kinase inhibitors, HCV protease inhibitors, and V1a receptor agonists. It has not undergone clinical trials and is not approved as a pharmaceutical. Its mechanism of action is chemical—serving as a protected amino acid building block for peptide synthesis.
|
| Molecular Formula |
C8H16N2O4
|
|---|---|
| Molecular Weight |
204.22
|
| Exact Mass |
204.111
|
| CAS # |
73259-81-1
|
| PubChem CID |
2755946
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
364.4±37.0 °C at 760 mmHg
|
| Melting Point |
210ºC (dec.)
|
| Flash Point |
174.2±26.5 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.489
|
| LogP |
0.84
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
14
|
| Complexity |
222
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(C)(OC(N[C@H](C(O)=O)CN)=O)C
|
| InChi Key |
KRJLRVZLNABMAT-YFKPBYRVSA-N
|
| InChi Code |
InChI=1S/C8H16N2O4/c1-8(2,3)14-7(13)10-5(4-9)6(11)12/h5H,4,9H2,1-3H3,(H,10,13)(H,11,12)/t5-/m0/s1
|
| Chemical Name |
(2S)-3-amino-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.8967 mL | 24.4834 mL | 48.9668 mL | |
| 5 mM | 0.9793 mL | 4.8967 mL | 9.7934 mL | |
| 10 mM | 0.4897 mL | 2.4483 mL | 4.8967 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
